業務
貨幣單位:EUR
2024/Q2
名稱營收比例
Research and development of T cell redirecting immunotherapies for the treatment of cancer1,875.5萬100.00%
地區
貨幣單位:EUR
2023/FY
名稱營收比例
BMS, United States5,069.5萬93.88%
Moderna, United States536.9萬9.94%
Genmab, Denmark-206.7萬-3.83%
